PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15270842-7 2004 Phorbol myristate acetate (PMA)-stimulated superoxide production by zymosan-induced peritoneal neutrophils and the levels of zymosan-induced tumour necrosis factor (TNF)-alpha and interleukin (IL)-1beta in peritoneal exudate fluids were also reduced in the diabetic mice. Zymosan 125-132 interleukin 1 beta Mus musculus 180-202 11290372-4 2001 We also demonstrated that a low dose of Db-cAMP, forskolin or dexamethasone inhibited the production of tumor necrosis factor-alpha and interleukin-1 beta by macrophages stimulated by zymosan. Zymosan 184-191 interleukin 1 beta Mus musculus 136-154 15187521-10 2004 MEASUREMENTS AND MAIN RESULTS: At 18 hrs after zymosan administration, we found a significant increase of peritoneal exudates, leukocyte infiltration in peritoneal cavity as well as an infiltration of neutrophils in lung and ileum tissues and subsequent lipid peroxidation, and increased production of plasma tumor necrosis factor-alpha and interleukin-1 beta. Zymosan 47-54 interleukin 1 beta Mus musculus 341-359 15034066-6 2004 Quantification of inflammatory mediator levels in homogenates of zymosan-stimulated tissues indicated reductions in levels of IL-1beta, KC, and macrophage inflammatory protein-1alpha in NE(-/-) mice. Zymosan 65-72 interleukin 1 beta Mus musculus 126-134 10633169-6 2000 These cells modulate the nociceptive response induced by zymosan and acetic acid via release of tumour necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 8. Zymosan 57-64 interleukin 1 beta Mus musculus 138-155 10633169-8 2000 In conclusion, our results suggest that the nociceptive activity of zymosan and acetic acid in the writhing model is due to the release of TNF-alpha, interleukin 1beta and interleukin 8 by resident peritoneal macrophages and mast cells. Zymosan 68-75 interleukin 1 beta Mus musculus 150-167 26573963-7 2016 RESULTS: The MPO(-/-) neutrophils stimulated by zymosan expressed and secreted significantly higher levels of MIP-1alpha, MIP-1beta, IL-1alpha, IL-1beta, and TNF-alpha than the stimulated wild-type cells. Zymosan 48-55 interleukin 1 beta Mus musculus 144-152 10344468-12 1999 Bone resorption stimulated by conditioned media from zymosan treated macrophages after 3 h was inhibited by 60-75% in the presence of anti IL-1alpha, 0-20% by anti IL-1beta, and completely by antisera neutralizing both IL-1alpha and IL-1beta. Zymosan 53-60 interleukin 1 beta Mus musculus 164-172 10344468-12 1999 Bone resorption stimulated by conditioned media from zymosan treated macrophages after 3 h was inhibited by 60-75% in the presence of anti IL-1alpha, 0-20% by anti IL-1beta, and completely by antisera neutralizing both IL-1alpha and IL-1beta. Zymosan 53-60 interleukin 1 beta Mus musculus 233-241 9613682-6 1998 The peritoneal lavage fluid (PLF) of SCF- mice also showed a marked increase in IL-1beta following zymosan administration, whereas local IL-6 and TNF-alpha production were not affected. Zymosan 99-106 interleukin 1 beta Mus musculus 80-88 9249578-1 1997 Interleukin (IL)-1 beta-deficient (IL-1 beta -/-) mice exhibited decreased zymosan-induced lethality and reduced production of IL-6 compared with wild-type controls (IL-1 beta +/+). Zymosan 75-82 interleukin 1 beta Mus musculus 35-44 9249578-2 1997 In addition, IL-1 beta -/- mice had a diminished cellular infiltrate (33%) in the peritoneal cavity after zymosan. Zymosan 106-113 interleukin 1 beta Mus musculus 13-22 9249578-9 1997 Our results demonstrate that IL-1 beta plays a significant, although not exclusive, role in the physiological and cytokine responses to zymosan-mediated inflammation. Zymosan 136-143 interleukin 1 beta Mus musculus 29-38 8581523-3 1995 TNF alpha and IL-1 beta reached a peak concentrations at 3 and 6 h respectively after zymosan injection. Zymosan 86-93 interleukin 1 beta Mus musculus 14-23 8581523-7 1995 Prednisolone inhibited IL-1 beta at 72 h post-zymosan. Zymosan 46-53 interleukin 1 beta Mus musculus 23-32 28903389-6 2017 Moreover, ISO abated zymosan-augmented lactate dehydrogenase activity, TNF-alpha and IL-1beta production, and apoptosis in WT AECs-II but not in HO-1- or STAT3-silenced cells. Zymosan 21-28 interleukin 1 beta Mus musculus 85-93 28381108-5 2017 Zymosan-induced inflammatory markers such as COX-2, TNFalpha, IL-1beta, and c-fos in the spinal cord were not altered by caloric restriction. Zymosan 0-7 interleukin 1 beta Mus musculus 62-70 9510087-10 1998 Quinacrine, and to a lesser extent chloroquine, has an inhibitory effect on the lipopolysaccharide- or zymosan-induced expression of interleukin 1beta and tumor necrosis factor alpha, both at the mRNA and protein levels. Zymosan 103-110 interleukin 1 beta Mus musculus 133-182 9029121-6 1997 In contrast, following zymosan-induced peritonitis, the levels of mature IL-1 beta were significantly lower in ICE -/- mice. Zymosan 23-30 interleukin 1 beta Mus musculus 73-82 9029121-8 1997 The reduced production of zymosan-induced mature IL-1 beta in ICE -/- mice was also observed from cultured peritoneal or spleen cells. Zymosan 26-33 interleukin 1 beta Mus musculus 49-58 8213352-7 1993 Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1 beta concentrations, but no effect of indomethacin. Zymosan 54-61 interleukin 1 beta Mus musculus 118-127 28861878-1 2017 In mice, two-hour immobilization stress inhibited zymosan-induced production by macrophages of the oxygen radicals and cytokine IL-1beta. Zymosan 50-57 interleukin 1 beta Mus musculus 128-136 27619992-4 2016 Studies of PMN infiltration during zymosan-induced peritonitis reveal that hyperglycemia enhances PMN recruitment not through inducing a high level of IL-17, which is the case in colitis, but through increasing F4/80+ macrophages in the peritoneal cavity, resulting in elevations of IL-6, IL-1beta, TNF-alpha, and CXCL1 production. Zymosan 35-42 interleukin 1 beta Mus musculus 289-297 25464008-9 2014 In contrast, FK506 reduced the expression of TREM-1, IL-1beta and TNFalpha in RAW264.7 macrophages stimulated with zymosan. Zymosan 115-122 interleukin 1 beta Mus musculus 53-61 22051147-8 2012 Moreover, the joint production of TNF-alpha, IL-1beta and CXCL1/KC by zymosan was dependent on TLR2/MyD88 signaling. Zymosan 70-77 interleukin 1 beta Mus musculus 45-53 22712758-9 2012 Neutrophil migration and cytokine release (TNF-alpha, IL-1beta and IL-6) induced by zymosan and fluid leakage induced by acetic acid were also reduced in BS-treated animals. Zymosan 84-91 interleukin 1 beta Mus musculus 54-62 21193041-7 2011 The degree of staining for nitrotyrosine, iNOS, PAR, TNF-alpha and IL-1beta was markedly reduced in tissue sections obtained from zymosan-injected mice, which had received olprinone. Zymosan 130-137 interleukin 1 beta Mus musculus 67-75 21703408-4 2011 In vitro, cytokine release from zymosan-stimulated macrophages was affected by AP214, with approximately 80%, 30%, and 40% reduction in IL-1beta, tumor necrosis factor-alpha, and IL-6, respectively. Zymosan 32-39 interleukin 1 beta Mus musculus 136-173 19819333-8 2010 PD98059 also attenuated the lung, liver and pancreatic injury and renal dysfunction caused by zymosan as well as the increase of TNF-alpha and IL-1beta plasma levels caused by zymosan. Zymosan 176-183 interleukin 1 beta Mus musculus 143-151 19721414-13 2009 IL-6 was by far the most induced acute-phase-cytokine in GD- and zymosan-treated livers, although IL-1beta and TNF-alpha were also strongly upregulated by zymosan and to a lesser extent by GD. Zymosan 155-162 interleukin 1 beta Mus musculus 98-106 19050619-15 2009 The degree of staining for nitrotyrosine, inducible nitric oxide synthase, poly (ADP-ribose), tumor necrosis factor-alpha, and interleukin-1beta were markedly reduced in tissue sections obtained from zymosan-injected mice, which had received EP. Zymosan 200-207 interleukin 1 beta Mus musculus 127-144 17363730-4 2007 The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF). Zymosan 43-50 interleukin 1 beta Mus musculus 228-236 17321468-3 2007 When cells are pre-treated with Con A and subsequently treated with TLR ligands--Zymosan A, PolyI:C, LPS, CpG DNA, there is enhanced production of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-12 and IFN-gamma,), nitric oxide and iNOS expression in murine peritoneal macrophages. Zymosan 81-90 interleukin 1 beta Mus musculus 185-193 17122962-14 2006 The increase in TNF-alpha, IL-1beta and CXCL8/IL-8 levels that were detected in knee synovial extracts obtained from zymosan-stimulated mice was also inhibited by TNTP (100 mg/kg, p. Zymosan 117-124 interleukin 1 beta Mus musculus 27-35